A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Inclusion Criteria: * Histologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC). * All forms of prior local therapy are allowed as long as patients have either a target lesion, which has not been treated with local therapy and/or the target lesion(s) within the field of the local-regional therapy has shown an increase of ≥ 20% in size. Local-regional therapy must be completed at least 4 weeks prior to the baseline CT scan. Local therapies including chemoembolization do not count as prior systemic therapy. * Are at least 4 weeks from major surgery and recovered. * At least one measureable lesion by RECIST 1.1. * Male or non-pregnant, non-breastfeeding female at least 18 years of age. Patients aged at 12\~18 years may be recruited but only at the site principle investigator's request and subject to Institutional Review Board (IRB) approval. * Has a pre-study echocardiogram or multi-gated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institutional lower limit of normal within one month of initiating therapy. * Have clinically acceptable laboratory screening results within certain limits specified below: * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN) * Total bilirubin ≤ 3.0 x ULN * Creatinine ≤ 1.5 x ULN or Cr Cl \> 60 cc/min * Absolute neutrophil count ≥ 1500 cells/mm3 * Platelets ≥ 50,000/mm3 * Have an Eastern Cooperative On…